197.87 USD
+1.31 (+0.67%)
Overall LGND gets a fundamental rating of 6 out of 10. We evaluated LGND against 191 industry peers in the Pharmaceuticals industry. While LGND belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. LGND is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes LGND very considerable for growth investing!
1. Profitability
1.1 Basic Checks
- In the past year LGND was profitable.
- In the past year LGND had a positive cash flow from operations.
- In multiple years LGND reported negative net income over the last 5 years.
- LGND had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of LGND (3.29%) is better than 83.25% of its industry peers.
- LGND's Return On Equity of 5.11% is amongst the best of the industry. LGND outperforms 83.25% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 1.58%, LGND is in the better half of the industry, outperforming 78.53% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for LGND is significantly below the industry average of 12.84%.
- The 3 year average ROIC (1.12%) for LGND is below the current ROIC(1.58%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.29% | ||
| ROE | 5.11% | ||
| ROIC | 1.58% |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
1.3 Margins
- LGND has a better Profit Margin (19.34%) than 90.58% of its industry peers.
- LGND's Operating Margin of 11.48% is amongst the best of the industry. LGND outperforms 84.29% of its industry peers.
- LGND's Operating Margin has declined in the last couple of years.
- LGND has a Gross Margin of 94.27%. This is amongst the best in the industry. LGND outperforms 96.34% of its industry peers.
- LGND's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.48% | ||
| PM (TTM) | 19.34% | ||
| GM | 94.27% |
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so LGND is destroying value.
- Compared to 1 year ago, LGND has more shares outstanding
- LGND has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, LGND has a worse debt to assets ratio.
2.2 Solvency
- LGND has an Altman-Z score of 5.78. This indicates that LGND is financially healthy and has little risk of bankruptcy at the moment.
- With a decent Altman-Z score value of 5.78, LGND is doing good in the industry, outperforming 75.92% of the companies in the same industry.
- LGND has a debt to FCF ratio of 14.48. This is a negative value and a sign of low solvency as LGND would need 14.48 years to pay back of all of its debts.
- LGND's Debt to FCF ratio of 14.48 is fine compared to the rest of the industry. LGND outperforms 77.49% of its industry peers.
- LGND has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
- LGND has a Debt to Equity ratio of 0.47. This is in the lower half of the industry: LGND underperforms 62.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 14.48 | ||
| Altman-Z | 5.78 |
ROIC/WACC0.17
WACC9.38%
2.3 Liquidity
- LGND has a Current Ratio of 24.69. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
- LGND has a Current ratio of 24.69. This is amongst the best in the industry. LGND outperforms 93.72% of its industry peers.
- A Quick Ratio of 24.30 indicates that LGND has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 24.30, LGND belongs to the top of the industry, outperforming 92.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 24.69 | ||
| Quick Ratio | 24.3 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 25.26% over the past year.
- Measured over the past years, LGND shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.44% on average per year.
- The Revenue has grown by 64.83% in the past year. This is a very strong growth!
- The Revenue has been growing slightly by 6.80% on average over the past years.
EPS 1Y (TTM)25.26%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%67.93%
Revenue 1Y (TTM)64.83%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%67.71%
3.2 Future
- The Earnings Per Share is expected to grow by 15.28% on average over the next years. This is quite good.
- The Revenue is expected to grow by 20.13% on average over the next years. This is a very strong growth
EPS Next Y30.63%
EPS Next 2Y21.4%
EPS Next 3Y19.77%
EPS Next 5Y15.28%
Revenue Next Year48.19%
Revenue Next 2Y27.54%
Revenue Next 3Y24.22%
Revenue Next 5Y20.13%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 27.14, the valuation of LGND can be described as expensive.
- 78.01% of the companies in the same industry are more expensive than LGND, based on the Price/Earnings ratio.
- LGND is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.94, which is the current average of the S&P500 Index.
- The Price/Forward Earnings ratio is 23.51, which indicates a rather expensive current valuation of LGND.
- 75.39% of the companies in the same industry are more expensive than LGND, based on the Price/Forward Earnings ratio.
- Compared to an average S&P500 Price/Forward Earnings ratio of 23.94, LGND is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.14 | ||
| Fwd PE | 23.51 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, LGND is valued a bit cheaper than the industry average as 76.96% of the companies are valued more expensively.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of LGND indicates a somewhat cheap valuation: LGND is cheaper than 75.39% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 126.6 | ||
| EV/EBITDA | 49.56 |
4.3 Compensation for Growth
- LGND's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of LGND may justify a higher PE ratio.
- A more expensive valuation may be justified as LGND's earnings are expected to grow with 19.77% in the coming years.
PEG (NY)0.89
PEG (5Y)2.02
EPS Next 2Y21.4%
EPS Next 3Y19.77%
5. Dividend
5.1 Amount
- LGND does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:LGND (1/21/2026, 1:49:38 PM)
197.87
+1.31 (+0.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-25 2026-02-25/amc
Inst Owners106.73%
Inst Owner Change1%
Ins Owners1.62%
Ins Owner Change-1.3%
Market Cap3.89B
Revenue(TTM)251.23M
Net Income(TTM)48.58M
Analysts85.71
Price Target248.31 (25.49%)
Short Float %6.48%
Short Ratio5.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.83%
Min EPS beat(2)10.36%
Max EPS beat(2)57.31%
EPS beat(4)4
Avg EPS beat(4)19.98%
Min EPS beat(4)4.63%
Max EPS beat(4)57.31%
EPS beat(8)8
Avg EPS beat(8)37.45%
EPS beat(12)12
Avg EPS beat(12)53.58%
EPS beat(16)15
Avg EPS beat(16)61.91%
Revenue beat(2)2
Avg Revenue beat(2)25.66%
Min Revenue beat(2)6.44%
Max Revenue beat(2)44.89%
Revenue beat(4)4
Avg Revenue beat(4)18.43%
Min Revenue beat(4)6.44%
Max Revenue beat(4)44.89%
Revenue beat(8)8
Avg Revenue beat(8)17.31%
Revenue beat(12)11
Avg Revenue beat(12)12.65%
Revenue beat(16)14
Avg Revenue beat(16)16.25%
PT rev (1m)2.5%
PT rev (3m)32.94%
EPS NQ rev (1m)0.4%
EPS NQ rev (3m)-23.57%
EPS NY rev (1m)-3.25%
EPS NY rev (3m)6.52%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)-10.47%
Revenue NY rev (1m)-5.71%
Revenue NY rev (3m)12.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.14 | ||
| Fwd PE | 23.51 | ||
| P/S | 15.5 | ||
| P/FCF | 126.6 | ||
| P/OCF | 122.01 | ||
| P/B | 4.1 | ||
| P/tB | 9.53 | ||
| EV/EBITDA | 49.56 |
EPS(TTM)7.29
EY3.68%
EPS(NY)8.41
Fwd EY4.25%
FCF(TTM)1.56
FCFY0.79%
OCF(TTM)1.62
OCFY0.82%
SpS12.77
BVpS48.28
TBVpS20.77
PEG (NY)0.89
PEG (5Y)2.02
Graham Number88.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.29% | ||
| ROE | 5.11% | ||
| ROCE | 1.99% | ||
| ROIC | 1.58% | ||
| ROICexc | 2.92% | ||
| ROICexgc | 9.48% | ||
| OM | 11.48% | ||
| PM (TTM) | 19.34% | ||
| GM | 94.27% | ||
| FCFM | 12.24% |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
ROICexc(3y)1.91%
ROICexc(5y)2.67%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)2.25%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.87%
ROICexc growth 5YN/A
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
F-Score5
Asset Turnover0.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 14.48 | ||
| Debt/EBITDA | 7.07 | ||
| Cap/Depr | 3.38% | ||
| Cap/Sales | 0.46% | ||
| Interest Coverage | 96.15 | ||
| Cash Conversion | 50.63% | ||
| Profit Quality | 63.32% | ||
| Current Ratio | 24.69 | ||
| Quick Ratio | 24.3 | ||
| Altman-Z | 5.78 |
F-Score5
WACC9.38%
ROIC/WACC0.17
Cap/Depr(3y)71.95%
Cap/Depr(5y)50.12%
Cap/Sales(3y)19.71%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.26%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%67.93%
EPS Next Y30.63%
EPS Next 2Y21.4%
EPS Next 3Y19.77%
EPS Next 5Y15.28%
Revenue 1Y (TTM)64.83%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%67.71%
Revenue Next Year48.19%
Revenue Next 2Y27.54%
Revenue Next 3Y24.22%
Revenue Next 5Y20.13%
EBIT growth 1Y64.02%
EBIT growth 3Y-33.67%
EBIT growth 5YN/A
EBIT Next Year674.52%
EBIT Next 3Y155.59%
EBIT Next 5Y79.19%
FCF growth 1Y-61.26%
FCF growth 3Y10.8%
FCF growth 5YN/A
OCF growth 1Y-66.41%
OCF growth 3Y7.19%
OCF growth 5YN/A
LIGAND PHARMACEUTICALS / LGND FAQ
What is the ChartMill fundamental rating of LIGAND PHARMACEUTICALS (LGND) stock?
ChartMill assigns a fundamental rating of 6 / 10 to LGND.
What is the valuation status of LIGAND PHARMACEUTICALS (LGND) stock?
ChartMill assigns a valuation rating of 5 / 10 to LIGAND PHARMACEUTICALS (LGND). This can be considered as Fairly Valued.
How profitable is LIGAND PHARMACEUTICALS (LGND) stock?
LIGAND PHARMACEUTICALS (LGND) has a profitability rating of 7 / 10.
What is the financial health of LIGAND PHARMACEUTICALS (LGND) stock?
The financial health rating of LIGAND PHARMACEUTICALS (LGND) is 6 / 10.